These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 1920085)

  • 1. A three-step approach combining Bayesian regression and NONMEM population analysis: application to midazolam.
    Maitre PO; Bührer M; Thomson D; Stanski DR
    J Pharmacokinet Biopharm; 1991 Aug; 19(4):377-84. PubMed ID: 1920085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of two population pharmacokinetic programs, NONMEM and P-PHARM, for tacrolimus.
    Staatz CE; Tett SE
    Eur J Clin Pharmacol; 2002 Dec; 58(9):597-605. PubMed ID: 12483452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Semi-mechanistic autoinduction model of midazolam in critically ill patients: population pharmacokinetic analysis.
    Aoyama T; Hirata K; Yamamoto Y; Yokota H; Hayashi H; Aoyama Y; Matsumoto Y
    J Clin Pharm Ther; 2016 Aug; 41(4):392-8. PubMed ID: 27178380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients.
    de Wildt SN; de Hoog M; Vinks AA; van der Giesen E; van den Anker JN
    Crit Care Med; 2003 Jul; 31(7):1952-8. PubMed ID: 12847388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Bayesian estimation in comparison to NONMEM for population pharmacokinetic data analysis: application to pefloxacin in intensive care unit patients.
    Bruno R; Iliadis MC; Lacarelle B; Cosson V; Mandema JW; Le Roux Y; Montay G; Durand A; Ballereau M; Alasia M
    J Pharmacokinet Biopharm; 1992 Dec; 20(6):653-69. PubMed ID: 1302767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetic analysis of meropenem in Japanese adult patients.
    Muro T; Sasaki T; Hosaka N; Umeda Y; Takemoto S; Yamamoto H; Kamimura H; Higuchi S; Karube Y
    J Clin Pharm Ther; 2011 Apr; 36(2):230-6. PubMed ID: 21366653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.
    Bustad A; Terziivanov D; Leary R; Port R; Schumitzky A; Jelliffe R
    Clin Pharmacokinet; 2006; 45(4):365-83. PubMed ID: 16584284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetic modeling in very premature infants receiving midazolam during mechanical ventilation: midazolam neonatal pharmacokinetics.
    Lee TC; Charles BG; Harte GJ; Gray PH; Steer PA; Flenady VJ
    Anesthesiology; 1999 Feb; 90(2):451-7. PubMed ID: 9952152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bayesian estimation of p-aminohippurate clearance by a limited sampling strategy.
    Kinowski JM; Rodier M; Bressolle F; Fabre D; Augey V; Richard JL; Galtier M; Gomen R
    J Pharm Sci; 1995 Mar; 84(3):307-11. PubMed ID: 7616369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients.
    Swart EL; Zuideveld KP; de Jongh J; Danhof M; Thijs LG; Strack van Schijndel RM
    Br J Clin Pharmacol; 2004 Feb; 57(2):135-45. PubMed ID: 14748812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
    Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetic modelling to assess clinical drug-drug interaction between AZD7325 and midazolam.
    Zhou D; Lu Z; Sunzel M; Xu H; Al-Huniti N
    J Clin Pharm Ther; 2014 Aug; 39(4):404-10. PubMed ID: 24689515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of ondansetron: a covariate analysis.
    de Alwis DP; Aarons L; Palmer JL
    Br J Clin Pharmacol; 1998 Aug; 46(2):117-25. PubMed ID: 9723819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the estimation of midazolam concentrations and pharmacokinetic parameters in intensive care patients using a bayesian pharmacokinetic software (PKS) according to sparse sampling approach.
    Bolon M; Bastien O; Flamens C; Paulus S; Salord F; Boulieu R
    J Pharm Pharmacol; 2003 Jun; 55(6):765-71. PubMed ID: 12841936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developing population pharmacokinetic parameters for high-dose methotrexate therapy: implication of correlations among developed parameters for individual parameter estimation using the Bayesian least-squares method.
    Watanabe M; Fukuoka N; Takeuchi T; Yamaguchi K; Motoki T; Tanaka H; Kosaka S; Houchi H
    Biol Pharm Bull; 2014; 37(6):916-21. PubMed ID: 24882404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance comparison of first-order conditional estimation with interaction and Bayesian estimation methods for estimating the population parameters and its distribution from data sets with a low number of subjects.
    Pradhan S; Song B; Lee J; Chae JW; Kim KI; Back HM; Han N; Kwon KI; Yun HY
    BMC Med Res Methodol; 2017 Dec; 17(1):154. PubMed ID: 29191177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer.
    Bressolle F; Joulia JM; Pinguet F; Ychou M; Astre C; Duffour J; Gomeni R
    Cancer Chemother Pharmacol; 1999; 44(4):295-302. PubMed ID: 10447576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pharmacokinetics of propofol in children using three different data analysis approaches.
    Kataria BK; Ved SA; Nicodemus HF; Hoy GR; Lea D; Dubois MY; Mandema JW; Shafer SL
    Anesthesiology; 1994 Jan; 80(1):104-22. PubMed ID: 8291699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient characteristics influencing ciclosporin pharmacokinetics and accurate Bayesian estimation of ciclosporin exposure in heart, lung and kidney transplant patients.
    Saint-Marcoux F; Marquet P; Jacqz-Aigrain E; Bernard N; Thiry P; Le Meur Y; Rousseau A
    Clin Pharmacokinet; 2006; 45(9):905-22. PubMed ID: 16928152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of midazolam in neonates.
    Burtin P; Jacqz-Aigrain E; Girard P; Lenclen R; Magny JF; Betremieux P; Tehiry C; Desplanques L; Mussat P
    Clin Pharmacol Ther; 1994 Dec; 56(6 Pt 1):615-25. PubMed ID: 7995003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.